(Q38210051)

31 August 2017

title

Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making? (English)

1 reference

31 August 2017

1 reference

personalized medicine

1 reference

Don Husereau

1

0 references

Deborah Marshall

object named as

Deborah A Marshall

2

0 references

Stuart Peacock

object named as

Stuart Peacock

4

0 references

Jeffrey S. Hoch

object named as

Jeffrey S Hoch

5

0 references

author name string

Adrian R Levy

3

1 reference

31 August 2017

publication date

1 April 2014

1 reference

International Journal of Technology Assessment in Health Care

31 August 2017

published in

1 reference

31 August 2017

volume

30

1 reference

31 August 2017

issue

2

1 reference

31 August 2017

page(s)

179-187

1 reference

Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

Economic evaluation of targeted cancer interventions: critical review and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

Assessing personalized medicines in Australia: a national framework for reviewing codependent technologies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

Implications of spillover effects within the family for medical cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

Guidelines for health technologies: specific guidance for oncology products in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

Valuing the benefits and costs of health care programmes: where's the 'extra' in extra-welfarism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

Understanding the medical and nonmedical value of diagnostic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

Do economic evaluations of targeted therapy provide support for decision makers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

Cost effectiveness of pharmacogenomics: a critical and systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

Value of information on preference heterogeneity and individualized care

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

Use of instrumental variables in the presence of heterogeneity and self-selection: an application to treatments of breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

Systematic review of pharmacoeconomic studies of pharmacogenomic tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

Cost-utility analyses of diagnostic laboratory tests: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

Health technology assessment in the era of personalized health care

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS (CHEERS) STATEMENT

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

A framework to evaluate the economic impact of pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

7 January 2021

Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

7 January 2021

Current methodological issues in the economic assessment of personalized medicine.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

7 January 2021

Health Care System Information Sharing: A Step Toward Better Health Globally

1 reference

https://api.crossref.org/works/10.1017%2FS0266462314000142

7 January 2021

10.1017/S0266462314000142

Identifiers

DOI

1 reference

31 August 2017

1 reference